August 8, 2017 05:02 PM EDT
R&D

War­ring with ex-CEO, op­tions shrink­ing, Aeter­na Zen­taris turns to a strate­gic re­view

John Carroll

Editor & Founder

Af­ter jet­ti­son­ing its failed lead ther­a­py and con­fronting its ex-CEO and gen­er­al coun­sel with al­le­ga­tions that they were try­ing to slip them­selves the old …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times